Monday , February 19 2018
Home / Letter From The Editor (page 18)

Letter From The Editor

August 16, 2016

If you are still stuck on the “metformin to start with and max out the dose” diabetes treatment algorithm, then you’d better take a look at this week’s homerun slides. Considering there are 11 distinct pathways to developing diabetes, it doesn’t make any sense that all our patients would only have …

Read More »

August 13, 2016

Last week the FDA announced that they were going to approve 6 different manufacturers for the production of rosuvastatin calcium, the generic version of Crestor. It appears that the FDA has decided that if they let more companies produce the generic, the price may not be as high to start …

Read More »

August 9, 2016

When a patient has a sudden and continued spike in glucose levels, we often look to check their insulin levels by ordering a C-Peptide test. We know that this test measures in vivo insulin based on the measurement of C-Peptide, which is co-secreted with insulin in equimolar amounts as a consequence …

Read More »

August 6, 2016

This past week, one of my favorite patients came back from a visit to Mississippi and was distraught. This patient was diagnosed with diabetes 6 years ago, and after significant weight loss he had to be placed on insulin. Being one of those people who believed he could “cure” his …

Read More »

August 2, 2016

We have all used the phrase “if you build it, they will come,” and when it comes to glucose monitoring systems and interconnectivity, it seems that every manufacturer has a belief that this is true. When Steve and Joy were at the recent ADA Scientific Sessions there were over 20 …

Read More »

July 30, 2016

There is an old saying in medicine: “above all do no harm.” This term often comes into play when our patients ask us about nutritional products for diabetes and other diseases, as well as when someone tells us about the greatest new exercise program to “cure” diabetes. This week we …

Read More »

July 26, 2016

There are various hormones, neurotransmitters, nucleotides, and fatty acids in the pancreas that affect insulin production and secretion. Sorting all these factors out, and how we might possibly affect glucose control by mimicking  some of these compounds, has opened up new avenues of treatment. GLP-1 agonists are just one example. This week in our …

Read More »

July 23, 2016

For many years, we have used finger sticks as the standard for diagnosis and management of diabetes. I can remember inviting patients to come to the pharmacy for a “diabetes day” where we offered free testing, and we would often find patients with elevated glucose levels. We would also spend …

Read More »

July 21, 2016

The dust has settled from the ADA scientific sessions in New Orleans and we have had time to look at what we learned about SGLT-2 Inhibitors. There were at least 40 posters on how they work and what they can do, but there was not a whole lot about clinical use. …

Read More »

Over the last 7 years we have heard all about the benefits of GLP-1 analogs. One of the benefits that is often touted is the increase in first phase insulin release. In simple terms, we define this as “the quick release of insulin at the first bite of food,” but …

Read More »